who discovered glp-1 Reflections on the discovery as a satiety hormone: Implications for obesity therapy and future directions The Discovery of Glucagon-Like Peptide

Semaglutide acts on the pancreas to reduce both pre- and post-prandial blood glucose concentrations in a glucose-dependent manner primarily by increasing insulin production and inhibiting the secretion of glucagon

However, factors such as poor diet, constant stress, and age can all deplete your bodys supply

The Payer Perspective: Payers, including insurers and healthcare systems, are becoming increasingly discerning when it comes to covering pharmaceutical treatments, especially for chronic conditions like obesity and diabetes

GLP-1RA interventions may reduce the incidence of recurrent AP, particularly SEMA and tirzepatide

Contact us today to get started.